Nebenwirkungen · Lunsumio
Lunsumio 1 mg concentrate for solution for infusion Lunsumio 30 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-148577 · Präparat HOS-099926
Across a broader clinical trial population, Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred in 2.1% (20/949) of patients, 19 patients had Grade 1-2 events and 1 patient had Grade 3 event. The majority of events occurred during the first cycle of treatment. The majority of cases resolved. The median time to onset from initial dose was 17 days (range: 1 to 48 days). The median duration was 3 days (range: 1-20 days). Immune Effector Cell-Associated Encephalopathy (ICE) scoring was not systematically performed across the referenced trial population.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:05:00Z · SHA-256 a2ee59741e6f5b14dd4aa21cd069422f86ba73f8dcfa924635f33b255e1e3671 · Passage 82ecb221adcb2a01fd9a62874b5a4640151e9b6b9d6589082f99f8da2cd7224e · Zeichen 12242–12817 im Abschnitt